Muscular Atrophy

·MeSH: Muscular Atrophy, Spinal

25 drugs in development·15 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Phase 3(7)

Drug	Company
apitegromab	Scholar Rock Holding Corp (SRRK)
Nusinersen	BIOGEN INC. (BIIB)
Nusinersen	Scholar Rock Holding Corp (SRRK)
Risdiplam	Scholar Rock Holding Corp (SRRK)
salanersen	BIOGEN INC. (BIIB)
Salanersen (BIIB115)	BIOGEN INC. (BIIB)
taldefgrobep alfa	Biohaven Ltd. (BHVN)

Phase 2(4)

Phase 1(2)

Drug	Company
AJ201	AVENUE THERAPEUTICS, INC. (ATXI)
avxs-101	AveXis, Inc. (AVXS)

Preclinical(3)

Drug	Company
ALPHA-0702	Alpha Cognition Inc. (ACOG)
ALPHA-0802	Alpha Cognition Inc. (ACOG)
stl-182	SPOTLIGHT INNOVATION INC. (STLT)

Phase 1/Phase 2(1)

Drug	Company
gb221	IMMAGE BIOTHERAPEUTICS CORP. (IMMG)

Phase 4(4)

Drug	Company
leuprorelin	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
leuprorelin	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
onasemnogene abeparvovec	NOVARTIS AG (NVSEF)
onasemnogene abeparvovec	Novartis AG (NVS)

BioSniper tracks 25 drugs in development for Muscular Atrophy across 15 companies.

There are 1 clinical trial targeting Muscular Atrophy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.